SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

SAN

101.08

+2.18%↑

EI

256

-3.51%↓

SHL.DE

48.16

-2.77%↓

ARGX

545

+3.69%↑

FRE

39.72

+2.8%↑

Search

Pharma Mar SA

Slēgts

78.95 -1.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

77.45

Max

80.1

Galvenie mērījumi

By Trading Economics

Ienākumi

5.7M

9.5M

Pārdošana

2.7M

48M

P/E

Sektora vidējais

1,996.25

73.239

EPS

1.063

Dividenžu ienesīgums

0.81

Peļņas marža

19.737

Darbinieki

500

EBITDA

8.2M

15M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+33% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.81%

3.06%

Nākamie ieņēmumi

2025. g. 22. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.4B

Iepriekšējā atvēršanas cena

80.45

Iepriekšējā slēgšanas cena

78.95

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Pharma Mar SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. apr. 23:15 UTC

Galvenie tirgus virzītāji

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025. g. 1. apr. 23:46 UTC

Tirgus saruna

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 1. apr. 23:44 UTC

Tirgus saruna

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025. g. 1. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025. g. 1. apr. 23:11 UTC

Top Ziņas

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025. g. 1. apr. 23:02 UTC

Tirgus saruna

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025. g. 1. apr. 22:31 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 1. apr. 22:26 UTC

Tirgus saruna

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025. g. 1. apr. 21:47 UTC

Top Ziņas

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025. g. 1. apr. 21:32 UTC

Top Ziņas

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025. g. 1. apr. 21:06 UTC

Tirgus saruna

Mexican Remittances See Slow Start to the Year -- Market Talk

2025. g. 1. apr. 21:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2025. g. 1. apr. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2025. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 1. apr. 20:47 UTC

Top Ziņas

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025. g. 1. apr. 20:47 UTC

Top Ziņas

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025. g. 1. apr. 20:20 UTC

Top Ziņas

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025. g. 1. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Eaton Completes Acquisition Of Fibrebond >ETN

2025. g. 1. apr. 20:11 UTC

Tirgus saruna

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025. g. 1. apr. 20:00 UTC

Top Ziņas

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025. g. 1. apr. 19:46 UTC

Top Ziņas

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025. g. 1. apr. 19:43 UTC

Tirgus saruna

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025. g. 1. apr. 19:17 UTC

Top Ziņas

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025. g. 1. apr. 19:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025. g. 1. apr. 19:03 UTC

Tirgus saruna

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025. g. 1. apr. 19:00 UTC

Tirgus saruna

Gold Slips Ahead of Tariff Day -- Market Talk

2025. g. 1. apr. 18:54 UTC

Tirgus saruna

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pharma Mar SA Prognoze

Cenas mērķis

By TipRanks

33% augšup

Prognoze 12 mēnešiem

Vidējais 107.997 EUR  33%

Augstākais 108 EUR

Zemākais 108 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pharma Mar SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

80.55 / 90.2Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.